[ad_1]
The new coronary pneumonia vaccine “BNT162b2” developed jointly by the US pharmaceutical company Pfizer (USA: PFE) and Germany’s BioNTech (USA: BNTX) is effective and the efficacy rate is currently above 90%. Pfizer has already signed vaccine supply agreements with many countries and the vaccines produced have been ordered. Although Hong Kong participates in the global access mechanism for the new corona vaccine (COVAX mechanism), it is worth noting thatPfizer and BioNTech have not confirmed their participation in the COVAX mechanism, which means that there are still many variables for Hong Kong to get the Pfizer vaccine quickly.
The Hong Kong government announced in September that it had submitted a letter of intent to participate in the global acquisition mechanism of the new corona vaccine (COVAX mechanism) to reserve potential vaccines for the public. On the other hand, it signed a pre-purchase agreement with individual vaccine manufacturers to obtain more supply to implement a “two-pronged vaccine procurement strategy”.
The results of Pfizer’s BioNTech vaccine clinical trials are amazing and the efficacy rate is over 90%, see[Pagina successiva]for details
Graphic illustration of the latest news from Tuesday’s major headlines
Zhang Jianzong: Funds have been reserved and no epidemic prevention measures will be relaxed at this stage
Chief Executive Officer Zhang Jianzong said before attending the executive meeting on Tuesday (10) that the Director of the Food and Health Bureau, Chen Zhaoshi, will hold a press conference on Wednesday morning to explain the progress of the outbreak, including the Hong Kong vaccine purchasing strategy. Zhang Jianzong said that if a large-scale safe and effective vaccine can be produced, it is gratifying news and the Hong Kong government has also allocated funds for the purchase. According to the third round of the Hong Kong government’s epidemic fund, the Hong Kong government has allocated 13 billion yuan to purchase vaccines.
Zhang Jianzong also pointed out that the outbreak in Hong Kong has not improved in the past week. Instead, there are hidden concerns about the invisible chain of transmission. He stressed that Hong Kong citizens have eased awareness of epidemic prevention and there is no room to relax existing epidemic prevention measures. Existing social distancing agreements such as the collection restriction order will continue for another week. He warned that in the event of a large-scale epidemic, the Hong Kong government must tighten anti-epidemic measures when forced to do nothing.
He reiterated that the Hong Kong government plans to implement 3 rounds of new measures this month: launch the “Travel with confidence” app, allow Hong Kong residents from the mainland or Macau to return to Hong Kong without being quarantined on the 14th and launch an “air travel bubble” measure with Singapore.
Cathay Pacific was up 20%, and mainland airline inventories all speculated to benefit from vaccines. For details, see[Pagina successiva]
Pfizer has not confirmed its participation in the COVAX mechanism
The COVAX mechanism is led by the Global Alliance for Vaccines and Immunization, the Alliance for Epidemic Prevention Innovation and the World Health Organization. It aims to promote the development and production of COVID-19 vaccines and ensure that all parts of the world receive an equitable distribution of vaccines and protect the most vulnerable groups. The vaccine will be delivered to participating countries and economies by the end of next year.
According to foreign media reports in September, Pfizer had expressed its intention to join COVAX, but has not updated the information since. At the same time, Pfizer and BioNTech have also signed vaccine supply agreements with many countries, and these countries are expected to receive the vaccines as soon as possible.
Pfizer announced that the signing of the vaccine agreement does not include Hong Kong
Countries or regions that have signed vaccine supply agreements with Pfizer and BioNTech include the United States, the European Union, New Zealand, Canada, and Australia.
The Hong Kong Food and Health Bureau had previously said that, according to the World Health Organization, there is still no vaccine for the prevention of COVID-19 approved for human use by regulatory agencies. However, the government expects global competition to be fierce after an effective vaccine is available. Therefore, it must be as soon as possible Act and participate in the COVAX mechanism can provide a certain degree of safety net for Hong Kong.
As the COVAX mechanism can only cover some citizens and the vaccine can only be delivered to Hong Kong before the end of next year, the government will manufacture vaccines in various regions through pre-purchase agreements based on scientific evidence and clinical data, after consultation. of the Scientific Committee of the Department of Health. Suppliers buy vaccines directly and look for additional supplies.
Related Articles︰
[Nuovo vaccino contro la corona]The efficacy rate of Huiduan BioNTech’s new corona vaccine has exceeded 90%. Apply for emergency clearance from the FDA by the end of the month. Pfizer will open 15% more (continuous update) [New Crown Vaccine]Two Chinese vaccines have entered Phase III clinical trials around the world. SASAC aims to actively expand vaccine manufacturing capacityDownload and use the “Hong Kong Economic Times” App for free and become a member, instantly receive the most accurate financial and current news and a variety of welcome gifts to choose from! https://bit.ly/2GhIwht
Short speculation promotion video, broadcast on the “Hong Kong Economic Times” app before the market opens every trading day, watch it now!
Publisher: Hou Jingcheng
[ad_2]
Source link
